Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Entera Bio Ltd. on August 28, 2021, covering the month of August 2021. The filing serves to furnish materials related to the company's Annual General Meeting of Shareholders scheduled for October 4, 2021, at its principal executive office in Jerusalem, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing containing corporate governance materials rather than a financial report.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this filing. The document focuses solely on the logistics and documentation for the upcoming shareholder meeting.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It incorporates by reference the Notice and Proxy Statement (Exhibit 99.1) and Proxy Card (Exhibit 99.2) for the Annual General Meeting.
Key Facts for Investors to Verify
- The Annual General Meeting is scheduled for October 4, 2021, at 5:00 p.m. Israel time.
- Dr. Spiros Jamas, Chief Executive Officer, signed the report on August 26, 2021.
- Investors should review the attached Notice and Proxy Statement (Exhibit 99.1) for details on matters to be voted upon at the meeting.
- This filing does not contain updated financial performance data; investors should refer to the most recent Form 20-F or quarterly reports for financial metrics.